Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Todd Baron

Gastroenterology Rochester, MN Medical Doctor

NPI 1356315279 CMS profile 106332

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$269,534

461 records reported · program years 2019–2025

Research payments

$2,250

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Todd Baron of Rochester, MN is reported in the CMS Open Payments database as having received $269,534 across 461 general payments and $2,250 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46,102 95
2024 General $42,509 78
2023 General $36,131 87
2022 General $52,583 74
2022 Research $2,250 2
2021 General $36,861 29
2020 General $40,140 41
2019 General $15,208 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Todd Baron
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Todd Baron were reported at $46,102. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Todd Baron Gastroenterology median Middle half National median
2019 $15,208 $417 $126–$1,100 $163
2020 $40,140 $224 $74–$624 $114
2021 $36,861 $352 $106–$1,054 $132
2022 $52,583 $448 $129–$1,270 $149
2023 $36,131 $533 $150–$1,390 $160
2024 $42,509 $605 $160–$1,606 $164
2025 $46,102 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $99,008 162 payments
  2. W. L. Gore & Associates, Inc. $66,688 64 payments
  3. Covidien LP $22,150 19 payments
  4. CONMED Corporation $19,679 26 payments
  5. Wilson Cook Medical Incorporated $18,043 10 payments
  6. Olympus America Inc. $17,543 54 payments
  7. Olympus Corporation of the Americas $10,101 54 payments
  8. Medtronic, Inc. $6,605 6 payments
  9. Olympus Corporation $4,261 8 payments
  10. Ambu Inc. $4,118 4 payments
  11. Other $1,339 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $142,228 71 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $73,805 38 payments
  3. Travel and Lodging $21,738 77 payments
  4. Honoraria $15,875 6 payments
  5. Food and Beverage $9,938 263 payments
  6. Education $5,951 6 payments
Products named General payments · program years 2019–2025
  1. GORE VIABIL Biliary Endoprosthesis $48,601 53 payments
  2. General - Therapies $34,328 30 payments
  3. D.A.S.H. $17,843 9 payments
  4. Axios $16,011 40 payments
  5. Olympus EUS Devices $11,934 12 payments
  6. Acquire $11,656 12 payments
  7. Olympus Biliary Devices $11,181 27 payments
  8. VIABIL Biliary Endoprosthesis $11,155 4 payments
  9. GORE VIABIL $11,037 3 payments
  10. Olympus EndoTherapy Accessories $10,537 8 payments
  11. Other $70,837 275 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $2,250 2 payments

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$46,345

Medicare's payments for the services billed

Medicare patients

130

Average age 71

Services billed

330

65 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 42%
Chronic kidney disease 40%
Depression 34%
Ischemic heart disease 32%
Cancer 22%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

463 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record